ERBB2 and ovarian cancer: In vitro, HER2-CAR-T cells exhibit robust targeted killing activity against a variety of solid tumors, including ovarian cancer (101), breast cancer (102), gastric cancer (33), pancreatic cancer (103), melanoma (104), glioblastoma (105), and head and neck cancer (106).